Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217

Fig. 4

Forest plot summarizing the effect of AADvac1 on outcomes in plasma p-tau217 ‘positive’ participants. A mixed model for repeated measures (MMRM) analysis was performed for changes in cognitive, volumetric and plasma biomarker outcomes at 104 weeks. Percent differences between the AADvac1 and placebo groups were plotted along with 95% CIs (error bars). Ctx, cortex

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193